Glenmark Pharmaceuticals Ltd
NSE: GLENMARK BSE: 532296
₹2268.40
(1.07%)
Mon, 12 Oct 2026, 09:28 pm
Market Cap (in Cr)64664.73
PE Ratio35.61
Dividend0.22
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1977
- Incorporated on November 18 as Glenmark Pharmaceuticals Private Limited.
1979
- Entered anti-fungal market with Candid Cream.
- Launched Candid Lotion, Candid V-3, Candid V-1, Candid V-Gel.
1981
- Launched Candid-B Cream.
1985
- Launched Candid Mouth Paint.
- Launched Ascoril cough expectorant.
1987
- Started Research and Development Department at Nasik factory.
1990
- Became deemed public company on July 1.
- Became private company on September 27.
- Launched Candiderma.
1991
- Deleted 'Private' from name on July 1.
1993
- Launched Candid Ear Drops.
- Proposed ERP system implementation with Sales, Distribution, Finance, Production, and MRP modules.
1995
- Launched Candid TV Suspension and Candidtral.
- Created Glenmark Pharmaceuticals Limited Employee Welfare Trust for ESOP.
1996
- Became Public Limited Company on January 12.
1997
- Established Cardiac Center in Dadar, Mumbai.
- Proposed drug discovery center in Thane-Belapur.
1999
- Proposed line extensions, new products, and Canada subsidiary.
- Allotted 175,000 warrants to Employee Welfare Trust.
- Launched Altacef, Suprocin, Suprocin B, Scalpe, Elovera.
- Public issue of 2,670,000 equity shares at Rs 200.
- Set up soft gel capsule facility in Goa and R&D center in Mumbai.
2000
- Shares listed on BSE at Rs 550.
- Entered strategic alliance with Haller Group Brazil.
- Issued 3,000,000 equity shares via private placement.
- Increased borrowing powers to Rs 150 crores.
- Acquired Alex, Flucort, and Sensur brands from Lyka Labs.
2001
- Board proposed private placement of 4,000,000 redeemable cumulative non-convertible preference shares.
2002
- Established proof of concept in animals for GRC-1087 anti-diabetic/anti-obesity agent.
- Co-opted Rajiv V Desai, A S Mohanty, and Sameer Paigankar to board.
- Robin Pinto resigned as director.
- CDC Financial Services acquired 2,500,000 convertible debentures.
2003
- Approved disinvestment of Goa manufacturing facilities.
- Forayed into US generics market.
- Declared 65% interim dividend.
- Allotted 21,000 ESOP equity shares.
- Entered marketing arrangement with Lannett Company US.
- Approved sub-division of equity shares from Rs 10 to Rs 2.
- Submitted Initial Drug Master File for Amiodarone.
- Fire at Kurkum factory suspended operations.
- Tied up with Apotex Canada for cardiac bulk drug supply.
- Converted debentures into 818,557 equity shares at Rs 305.42.
2004
- Glenmark Pharmaceuticals Inc. USA signed development and marketing agreement with KV Pharmaceutical.
- Acquired Laboratories Klinger in Brazil for $5.2 million.
- Acquired two FDA-approved products from Clonmel Healthcare Ltd.
- Glenmark Pharmaceuticals SA entered collaboration with Forest Laboratories for GRC 3886.
2005
- Forged alliance with 2 US firms for US product sales.
- Announced collaboration with Teijin Pharma on GRC 3886.
- Glenmark Pharmaceuticals SA acquired Servycal SA in Argentina.
- Signed development and marketing agreement with InvaGen.
- Issued 1:1 bonus.
2006
- Glenmark USA acquired exclusive marketing rights to 3 generic products.
- Signed $27 million royalty deal with Paul Capital for US generic dermatology portfolio.
- US subsidiary inked agreement with Lehigh.
- Planned acquisition of generic company in Europe.
- Joined hands with US firm.
2007
- Received tentative USFDA approval for Topiramate Tablets.
- Received MHRA UK approval for Baddi semi-solids plant.
- Out-licensed GRC 6211 to Eli Lilly for $350 million deal.
- Split face value from Rs 2 to Rs 1.
2008
- Launched Nabumetone and Hydroxyzine Hydrochloride Tablets.
- Launched Clobetasol from dermatology pipeline.
- Launched trandolapril tablets.
- Subsidiary received USFDA approval for Betamethasone Dipropionate Cream 0.05% Augmented.
2009
- M J Mendonza joined as VP Legal & Company Secretary.
- Received ANDA approval for Alclometasone Dipropionate Cream 0.05%.
- Appointed D R Mehta and B E Saldanha as Additional Directors.
- Received ANDA approval for Verapamil 240 mg ER tablets.
2010
- Entered settlement and license agreement with Sepracor for generic Eszopiclone tablets.
2011
- Won two SCRIP Awards.
- Exercised purchase option in royalty agreement with Paul Capital.
- Forayed into Cosmeceutical Segment.
- GBR 500 deal cleared under Hart-Scott-Rodino Act.
2012
- Signed development agreement with Forest Laboratories for novel agents treating chronic inflammatory conditions.
- Settled Paragraph IV litigation with Janssen Pharmaceuticals.
- Received tentative approval for zolmitriptan orally disintegrating tablets.
- Won arbitration claim against Napo.
2013
- Launched Hydrocortisone Butyrate cream in US.
- Announced discovery and IND-enabling studies of OX40-targeting monoclonal antibody.
- USFDA approved Crofelemer 125 mg delayed-release tablets for HIV/AIDS diarrhea.
- Received ANDA approval for Mupirocin Calcium Cream USP 2%.
- Atovaquone Proguanil (Malarone) patent revoked; launched first UK generic.
- Initiated IND-enabling studies of novel monoclonal antibody.
2014
- Merged subsidiaries Glenmark Generics Ltd. and Glenmark Access Ltd. with Glenmark Pharmaceuticals Ltd.
- Entered Oncology with discovery of bispecific Antibody.
- Inaugurated Antibody Manufacturing Facility in La Chaux-de-Fonds, Switzerland.
- USFDA granted final ANDA acceptance.
- Received $5 million milestone payment from Sanofi for VLA2 monoclonal antibody.
- Received USFDA approval for skin infection cream.
2015
- Approved and launched Ashlyna Extended-Cycle Oral Contraceptive Tablets in US.
- Approved and launched Trandolapril & Verapamil HCl ER Tablets in US.
- Received USFDA approval for Salmecort MDI Inhaler in Russia.
- CCEA approved foreign investment proposals worth Rs 4187 crore.
- Certified Scheme of Arrangement merging Glenmark Generics Ltd. and Glenmark Access Ltd. with Glenmark Pharmaceuticals Ltd.
- Announced strategic development and licensing agreement with Celon Poland for generic Seretide Accuhaler in Europe.
- Received tentative ANDA approval for Lacosamide Tablets 50 mg, 100 mg, 150 mg, 200 mg.
- Received ANDA approval for Clotrimazole and Betamethasone Dipropionate Cream USP 1%/0.05%.
- Entered settlement agreement with Forest Laboratories and Royalty Pharma.
2016
- Received tentative USFDA approval for anti-arrhythmic drug.
- Discovered new molecule.
- Received USFDA approval for cancer treatment drug.
- Received approval for Raloxifene tablets.
- Received 3 USFDA observations for Indore plant.
- Received approval for Triamcinolone Acetonide Ointment.
- Launched first generic Zetia in US.
- Received approval for Tretinoin Capsules.
2017
- Announced partnership with Evestra for generic NuvaRing.
- Entered agreement with APC Therapeutics.
- Entered exclusive agreement with Cyndea Pharma for generic soft-gelatin capsules.
- Launched nicotine substitute gum.
2018
- Launched Nourkrin in Russia.
- Launched biosimilar Adalimumab in India.
- Entered exclusive collaboration with SCD Pharmaceuticals South Korea for ophthalmic products.
- Launched generic Seretide Accuhaler in Denmark.
- Collaborated with True North for orthopaedic and pain management business in India.
2019
- Entered licensing agreement with Yuhan for Ryaltris in South Korea.
- Signed licensing agreement with Torrent for co-marketing Remogliflozin Etabonate in India.
- Secured Dow Jones Sustainability Emerging Markets Index for second year.
2020
- First to launch Remogliflozin + Vildagliptin FDC for Type 2 Diabetes in India.
- Introduced NINDANIB (Nintedanib) for Pulmonary Fibrosis in India.
- Introduced 400 mg strength FabiFlu for COVID-19 treatment.
- Received USFDA approval for Deferasirox tablets for oral suspension.
- Pledged 50 lakh meals amid COVID-19 pandemic.
- Entered exclusive licensing agreement with Hikma for Ryaltris in US.
2021
- Awarded International Safety Award.
- Awarded Environmental, Social and Governance Summit & Awards.
- Launched Rufinamide Tablets USP 200 mg and 400 mg.
- Launched Ryaltris nasal spray in India.
2022
- Received USFDA approval for Nicardipine Hydrochloride capsules.
- Received ANDA approval for generic birth control drug.
- Received India Pharma Innovation of the Year Award from Government of India.
- First to launch Triple FDC Teneligliptin + Pioglitazone + Metformin for Type 2 Diabetes in India.
- Launched Fingolimod Capsules 0.5 mg in US.
2023
- Launched Bumetanide Injection USP 1 mg/4 mL and 2.5 mg/10 mL in US.
2024
- Received US health regulator approval for generic stomach acid medication.
- Launched Lacosamide Oral Solution 10 mg/mL in US.
- Launched Travoprost Ophthalmic Solution USP 0.004% in US.
- Received ANDA approval for Topiramate Capsules USP 15 mg and 25 mg.
- Entered agreement with BeiGene for marketing and distribution of Tislelizumab and Zanubrutinib in India.
